Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

Literature DB >> 15503113

CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

A Martínez-Yélamos, A Rovira, R Sánchez-Valle, S Martínez-Yélamos, M Tintoré, Y Blanco, F Graus, X Montalban, T Arbizu, A Saiz.

Abstract

Entities: Species

Mesh：

Substances：
14-3-3 Proteins

Year: 2004 PMID： 15503113 DOI： 10.1007/s00415-004-0524-y

Source DB: PubMed Journal: J Neurol ISSN： 0340-5354 Impact factor: 4.849

× No keyword cloud information.

10 in total

1. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis.

Authors: A Martínez-Yélamos; A Saiz; R Sanchez-Valle; V Casado; J M Ramón; F Graus; T Arbizu
Journal: Neurology Date: 2001-08-28 Impact factor: 9.910

2. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.

Authors:
Journal: Neurology Date: 2002-10-08 Impact factor: 9.910

3. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

Authors: B G Weinshenker; G P Rice; J H Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal: Brain Date: 1991-04 Impact factor: 13.501

Review 4. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

Authors: F Barkhof; M Filippi; D H Miller; P Scheltens; A Campi; C H Polman; G Comi; H J Adèr; N Losseff; J Valk
Journal: Brain Date: 1997-11 Impact factor: 13.501

5. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors: C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal: Ann Neurol Date: 1983-03 Impact factor: 10.422

6. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors: G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal: Lancet Date: 2001-05-19 Impact factor: 79.321

7. Short-term prognosis in early relapsing-remitting multiple sclerosis.

Authors: T F Scott; C J Schramke; J Novero; C Chieffe
Journal: Neurology Date: 2000-09-12 Impact factor: 9.910

8. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Authors: Frederik Barkhof; Mara Rocca; Gordon Francis; Jan-Hein T M Van Waesberghe; Bernard M J Uitdehaag; Otto R Hommes; Hans-Peter Hartung; Luca Durelli; Gilles Edan; Oscar Fernández; Pierette Seeldrayers; Per Sørensen; Simon Margrie; Marco Rovaris; Giancarlo Comi; Massimo Filippi
Journal: Ann Neurol Date: 2003-06 Impact factor: 10.422

9. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI.

Authors: P A Brex; K A Miszkiel; J I O'Riordan; G T Plant; I F Moseley; A J Thompson; D H Miller
Journal: J Neurol Neurosurg Psychiatry Date: 2001-03 Impact factor: 10.154

10. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422

10 in total

11 in total

CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

1. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis.

2. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.

3. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

Review 4. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.

5. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

6. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

7. Short-term prognosis in early relapsing-remitting multiple sclerosis.

8. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

9. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI.

10. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

1. A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases.

Review 2. Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Review 3. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

4. Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Review 5. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

6. Role of glial 14-3-3 gamma protein in autoimmune demyelination.

Review 7. The Cerebrospinal Fluid in Multiple Sclerosis.

8. Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.

9. Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b.

Review 10. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.